Comparison of One-Year Outcome (Death and Rehospitalization) in Hospitalized Heart Failure Patients With Left Ventricular Ejection Fraction >50% Versus Those With Ejection Fraction <50%

American Journal of Cardiology

Volumn 102, Issue 1, 2008, Pages 79-83

  Ezekowitz, Justin A ^a   Lee, Douglas S ^b   Tu, Jack V ^b   Newman, Alice M ^b   McAlister, Finlay A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CANADA; CONTROLLED STUDY; FEMALE; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOTONIC AGENTS; DIGOXIN; DIURETICS; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PATIENT READMISSION; SPIRONOLACTONE; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME;

EID: 50949090219     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.02.102     Document Type: Article

References (21)

1. Bhatia R.S., Tu J.V., Lee D.S., Austin P.C., Fang J., Haouzi A., Gong Y., and Liu P.P. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355 (2006) 260-269
2. Yusuf S., Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J., Michelson E.L., Olofsson B., Ostergren J., and CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362 (2003) 777-781
3. Cleland J.G., Tendera M., Adamus J., Freemantle N., Polonski L., and Taylor J. The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study. Eur Heart J 27 (2006) 2338-2345
4. Lee D.S., Austin P.C., Rouleau J.L., Liu P.P., Naimark D., and Tu J.V. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 290 (2003) 2581-2587
5. McKee P.A., Castelli W.P., McNamara P.M., and Kannel W.B. The natural history of congestive heart failure: the Framingham study. N Engl J Med 285 (1971) 1441-1446
6. Packer M., Coats A.J., Fowler M.B., Katus H.A., Krum H., Mohacsi P., Rouleau J.L., Tendera M., Castaigne A., Roecker E.B., Schultz M.K., and DeMets D.L. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
7. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353 (1999) 9-13
8. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
9. Sin D.D., and McAlister F.A. The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure. Am J Med 113 (2002) 650-656
10. McAlister F.A., Ghali W.A., Gong Y., Fang J., Armstrong P.W., and Tu J.V. Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure. Circulation 113 (2006) 2572-2578
11. Ahmed A., Rich M.W., Fleg J.L., Zile M.R., Young J.B., Kitzman D.W., Love T.E., Aronow W.S., Adams Jr. K.F., and Gheorghiade M. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary Digitalis Investigation Group trial. Circulation 114 (2006) 397-403
12. Fuster V., Ryden L.E., Cannom D.S., Crijns H.J., Curtis A.B., Ellenbogen K.A., Halperin J.L., Le Heuzey J.Y., Kay G.N., Lowe J.E., et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114 (2006) e257-e354
13. Zile M.R., and Brutsaert D.L. New concepts in diastolic dysfunction and diastolic heart failure: part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 105 (2002) 1387-1393
14. Vasan R.S., and Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 101 (2000) 2118-2121
15. Paulus W.J., Tschope C., Sanderson J.E., Rusconi C., Flachskampf F.A., Rademakers F.E., Marino P., Smiseth O.A., De K.G., Leite-Moreira A.F., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28 (2007) 2539-2550
16. McMurray J., Carson P., Komajda M., McKelvie R., Zile M., Ptaszynska A., Staiger C., Donovan J., and Massie B. Heart failure with preserved ejection fraction: Clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure 10 (2008) 149-156
17. Carson P., Massie B.M., McKelvie R., McMurray J., Komajda M., Zile M., Ptaszynska A., and Frangin G. The Irbesartan in heart failure with Preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail 11 (2005) 576-585
18. Flather M.D., Shibata M.C., Coats A.J., van Veldhuisen D.J., Parkhomenko A., Borbola J., Cohen-Solal A., Dumitrascu D., Ferrari R., Lechat P., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26 (2005) 215-225
19. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., and Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (2000) 145-153
20. D'Agostino Jr. R.B. Propensity scores in cardiovascular research. Circulation 115 (2007) 2340-2343
21. Granger B.B., Swedberg K., Ekman I., Granger C.B., Olofsson B., McMurray J.J., Yusuf S., Michelson E.L., and Pfeffer M.A. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet 366 (2005) 2005-2011